B

BioInvent International AB
STO:BINV

Watchlist Manager
BioInvent International AB
STO:BINV
Watchlist
Price: 50.4 SEK 0.9% Market Closed
Market Cap: 3.3B SEK
Have any thoughts about
BioInvent International AB?
Write Note

Relative Value

The Relative Value of one BINV stock under the Base Case scenario is 6.66 SEK. Compared to the current market price of 50.4 SEK, BioInvent International AB is Overvalued by 87%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BINV Relative Value
Base Case
6.66 SEK
Overvaluation 87%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
7
vs Industry
22
Median 3Y
17.5
Median 5Y
15.8
Industry
8.1
Forward
66.4
vs History
vs Industry
Median 3Y
-8.5
Median 5Y
-8.5
Industry
23
Forward
-12.6
vs History
vs Industry
Median 3Y
-9.6
Median 5Y
-9.6
Industry
23.4
vs History
vs Industry
Median 3Y
-9
Median 5Y
-9
Industry
27.3
vs History
19
vs Industry
39
Median 3Y
1.5
Median 5Y
1.9
Industry
2.6
vs History
6
vs Industry
23
Median 3Y
5.7
Median 5Y
7.4
Industry
8.1
Forward
47.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
24
Median 3Y
-5.1
Median 5Y
-5.5
Industry
4.3
Forward
-6.2
vs History
vs Industry
22
Median 3Y
-4.8
Median 5Y
-5
Industry
3.8
Forward
-6.2
vs History
vs Industry
26
Median 3Y
-5.8
Median 5Y
-6.1
Industry
6
vs History
vs Industry
23
Median 3Y
-5.6
Median 5Y
-5.8
Industry
3.8
vs History
17
vs Industry
27
Median 3Y
2.8
Median 5Y
4.9
Industry
4.8

Multiples Across Competitors

BINV Competitors Multiples
BioInvent International AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
BioInvent International AB
STO:BINV
3.3B SEK 85.8 -8.1 -5.4 -5.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59.1 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 4.9 37.5 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 11.9 -264.2 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 4.1 912.5 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 6.4 19 17.4 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
SE
B
BioInvent International AB
STO:BINV
Average P/E: 212.4
Negative Multiple: -8.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.1
412%
US
Amgen Inc
NASDAQ:AMGN
37.5
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -264.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
912.5
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
B
BioInvent International AB
STO:BINV
Average EV/EBITDA: 17.9
Negative Multiple: -5.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
SE
B
BioInvent International AB
STO:BINV
Average EV/EBIT: 23.2
Negative Multiple: -5.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top